TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Klerfalk Pharma AB
Closing information (x1000 EUR)
Closing information | 2023/12 | 2022/12 | 2021/12 |
Turnover | 96 | 102 | 160 |
Financial expenses | 267 | 48 | 304 |
Earnings before taxes | 15 | -31 | 665 |
EBITDA | 7 | 15 | 59 |
Total assets | 1,055 | 1,046 | 1,184 |
Current assets | 60 | 109 | 165 |
Current liabilities | 33 | 42 | 55 |
Equity capital | 1,012 | 992 | 1,118 |
- share capital | 5 | 4 | 5 |
Employees (average) | 1 | 1 | 1 |
Financial ratios
Fiscal year | 2023/12 | 2022/12 | 2021/12 |
Solvency | 95.9% | 94.8% | 94.4% |
Turnover per employee | 96 | 102 | 160 |
Profit as a percentage of turnover | 15.6% | -30.4% | 415.6% |
Return on assets (ROA) | 26.7% | 1.6% | 81.8% |
Current ratio | 181.8% | 259.5% | 300% |
Return on equity (ROE) | 1.5% | -3.1% | 59.5% |
Change turnover | -6 | -45 | 51 |
Change turnover % | -6% | -31% | 47% |
Chg. No. of employees | 0 | 0 | 0 |
Chg. No. of employees % | 0% | 0% | 0% |
Total value of public sale
Fiscal year | 2023/12 | 2022/12 | 2021/12 |
Total value of public sale | 0 | 0 | 0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.